Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF).

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the ...